fashion -WSS

fashion

author：hotspot 2025-09-29 21:29:19 - browse：2

Drugmakers already bet big on mRNA for cancer. Now President Biden is going in, too? Anna Moneymaker/Getty Images

WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its sights on one of the hottest areas of medicine — and one where the drug industry has a multibillion-dollar head start.

The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target “cancer and other diseases,” investing in the technology behind the U.S.’s most commonly used vaccines for Covid-19.

The administration touted the news of CUREIT as the latest in Biden’s longtime mission to rein in cancer deaths, the Cancer Moonshot. But by using mRNA to treat cancer, ARPA-H is wading into a field that has advanced in fits and starts — and whose industry leaders have already spent multiples of the program’s entire budget into their own research. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Chinese researcher claims birth of first gene

focus

hotspot

WSS

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Biotech investment managers search for lucrative opportunities

Medical devices makers are asking for forgiveness, not permission

Texas board proposes rules on abortion law emergency exemption

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medicare threatens to cut off funding for HCA's Mission hospital

Wikipedia

fashion

Wikipedia

Affirmative action in medical school literally saved lives

Adam's Take: Intra

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Peter Hotez and the public health issue of online harassment

Yancopoulos of Regeneron works to expand Dupixent success

At least 13 dead in Texas as scorching temps continue

U.K. officials, researchers try to ease path for bespoke genetic treatments

23andMe had bad news about my health. I wish a person had delivered it

Adam's Take: Intra

hotspot

Pregnancy ages women, but effects reverse after delivery

What we’ve learned from the Aduhelm mess

PhRMA lawsuit over Medicare drug price negotiation tossed

What should King Charles tell the public about his cancer?

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Why did Pfizer dish out millions for a Super Bowl ad?

leisure time

focus

hotspot

focus